Cargando…
P1212: RATIONALLY DESIGNED CHIMERIC PI3K-BET BROMODOMAIN INHIBITORS ELICIT CURATIVE RESPONSES IN MYC-DRIVEN LYMPHOMA
Autores principales: | Oh, Danielle H., MA, Xiao, He, Jackson, Kearney, Conor, Hogg, Simon J., Newbold, Andrea, Fraser, Peter, Jennings, Ian G., Brasacchio, Daniella, Susanto, Olivia, Yew Fong, Chun, Dawson, Mark A., Gruber, Emily, Kats, Lev, Johnstone, Ricky W., Thompson, Philip E., Shortt, Jake |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430981/ http://dx.doi.org/10.1097/01.HS9.0000971744.43694.69 |
Ejemplares similares
-
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
por: Hogg, Simon J., et al.
Publicado: (2022) -
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
por: Hogg, Simon J., et al.
Publicado: (2017) -
Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010) -
BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014) -
Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)